Antimicrobial peptides (AMPs) are the most active area of non-GLP-1 peptide drug development. They hit pathogens — including carbapenem-resistant gram-negatives — by mechanisms small-molecule antibiotics cannot match: membrane disruption, biofilm penetration, and rapid bactericidal activity that makes resistance evolution slower.
Programs covered on this site include Peptilogics' work on prosthetic-joint biofilm, Fedora Pharmaceuticals' FPI-2119 lactivicin against gram-negative organisms, the HMD-AMP discovery platform from HLB Innovation (Nature Biomedical Engineering), and academic programs on persister-cell killing, MRSA, and Acinetobacter baumannii.
The gap is delivery and clinical economics. Most AMP candidates run into instability or selectivity ceilings before Phase 2. The ones moving fastest combine novel scaffolds with AI-driven design. See #amr and #antibiotic-resistance for resistance context.
Frontiers in Medicine 2026 comprehensive review on antimicrobial peptides (AMPs) as cancer treatments and vaccines synthesizes the growing body of preclinical and early-clinical evidence. Mechanism synthesis: AMPs are cationic (positively charged) amphipathic (both water-loving and lipid-loving) peptides that selectively interact with the negatively charged phospholipid outer leaflets of malignant cell membranes (produced by higher phosphatidylserine externalization in cancer cells compared to normal cells). This selectivity produces cytotoxicity through membrane disruption, followed by intracellular actions including inhibition of DNA replication and protein synthesis, induction of mitochondrial dysfunction (opening the mitochondrial permeability transition pore to release cytochrome c and trigger apoptosis), and suppression of tumor angiogenesis (reducing tumor vascular supply). The review extends the AMP-anticancer research trajectory anchored by the August 7, 2026 Nature aMPC16-CA50 synthetic acid-responsive membranolytic peptide study and recent MDPI Antibiotics coverage of frog-skin AMP families (dermaseptins from Phyllomedusa frogs, temporins from Rana temporaria, brevinins from Rana and Sylvirana). Ongoing translation challenges include high systemic toxicity at effective anticancer doses (requiring tumor-selective delivery), poor systemic stability (peptidase degradation in blood), limited cellular penetration (large hydrophilic molecules), and costly synthesis (multi-step solid-phase peptide synthesis at gram-scale). Mechanism diversity across natural-origin, synthetic (using natural templates), and AI-designed AMPs (using machine learning to design novel sequences with optimized properties) continues to expand the therapeutic pipeline.
MDPI Antibiotics published a review paper synthesizing the dual antimicrobial-and-anticancer activity of frog-skin-derived peptides. The paper covers three main families: dermaseptins (originally isolated from Phyllomedusa frogs and studied since the 1990s), temporins (small linear peptides typically 10-14 amino acids from Rana temporaria and related species), and brevinins (larger amphipathic peptides from Rana and Sylvirana genera). Mechanism synthesis: the peptides disrupt microbial membranes through broad-spectrum cationic amphipathic activity against multidrug-resistant bacteria while also selectively targeting cancer cells through electrostatic interactions with the negatively charged phospholipid outer leaflets that are characteristic of many cancer cell membranes. Cancer-cell membrane disruption is followed by apoptosis or necrosis induction in ways that differ from traditional cytotoxic chemotherapy. The frog-skin AMP family represents one of the most-studied natural sources of bioactive antimicrobial peptides with cross-category therapeutic potential. The review extends the broader anticancer AMP research trajectory anchored by the August 7, 2026 Nature paper on the aMPC16-CA50 synthetic acid-responsive membranolytic peptide that induces immunogenic cell death and the Frontiers in Medicine 2026 comprehensive review on AMPs as cancer therapeutics and vaccine adjuvants. Clinical translation challenges remain (high toxicity at effective anticancer doses, poor systemic stability, limited cellular penetration, and costly synthesis) but the mechanism-of-action diversity across dermaseptins, temporins, and brevinins provides a broad pipeline for continued preclinical and early-clinical work.
A University of Alberta research team published preclinical data in Cell Biomaterials on D-GK17, a human-derived antimicrobial peptide that targets bacterial and fungal biofilms. Biofilms are the sticky extracellular matrix bacterial and fungal communities create that render traditional antibiotic treatments substantially less effective; biofilm-associated infections drive a major portion of antimicrobial resistance and hospital-acquired infection burden. D-GK17 demonstrated stability, non-toxicity to human cells, and broad-spectrum activity against multidrug-resistant pathogens in the preclinical work. The team is filing a patent through the University of Alberta and developing gel and bandage delivery formulations for skin infections and cancer-treatment-related mouth ulcers (chemotherapy and radiation-induced oral mucositis is a substantial unmet-need indication in oncology). D-GK17 extends the rapidly-growing antimicrobial peptide therapeutic category, which the FDA PCAC February 2027 docket also advances via the cathelicidin (LL-37) peptide review. The AMP category is under active development across marine-derived (shrimp SALF-based), computational (MAC-AMP AI design system), and human-derived platforms, with cross-cutting applications spanning antimicrobial resistance, cancer therapy, and antiviral therapy.
The FDA Pharmacy Compounding Advisory Committee (PCAC) has scheduled a second peptide meeting before the end of February 2027 to review five additional peptides for Section 503A Bulks List inclusion. The February 2027 docket covers: cathelicidin (LL-37), a broad-spectrum antimicrobial peptide with anti-infective and immune-modulatory activity; GHK-Cu (glycyl-histidyl-lysine copper tripeptide), a widely-marketed cosmetic and wound-healing peptide previously in FDA Category 2; dihexa acetate, an angiotensin IV-derived nootropic that has been marketed for cognitive enhancement; melanotan II, an alpha-melanocyte-stimulating hormone analog marketed for skin pigmentation (self-tanning) and appetite suppression; and pegylated mechano growth factor (PEG-MGF), a muscle-repair peptide derived from insulin-like growth factor 1 splice variants. The February 2027 review continues the July 23-24, 2026 PCAC session that recommended 6 of 7 peptides for Section 503A Bulks List inclusion (BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon approved; Emideltide/DSIP rejected). FDA has not yet posted the final date and public-comment docket details for the February 2027 meeting. Under standard rulemaking timelines, the FDA's process of Notice of Proposed Rulemaking, public comment period, and final rule after any positive PCAC recommendation takes 12-24 months.
A January 2026 Frontiers in Cellular and Infection Microbiology review synthesized the case for antimicrobial peptides (AMPs) as the most promising response to antimicrobial resistance, which is responsible for nearly 5 million deaths annually and projected to double by 2050. The review emphasizes that AMPs' rapid, multi-target mechanism — primarily physical membrane disruption — produces significantly lower incidence of resistance emergence than traditional small-molecule antibiotics. The pipeline now exceeds 150 active candidates spanning AI-designed AMPs, lysin-derived peptides, and venom-derived sequences.
A recent PubMed-indexed study reports that Mu-17 — a novel antimicrobial peptide designed using a bio-inspired approach based on scorpion AMP leucine-zipper-like motifs — showed both antimicrobial and anticancer activity with reduced toxicity. Mu-17 inhibited breast cancer cell proliferation with IC50 of 13 µM and exhibited remarkably low hemolytic activity (18% at 100 µM). The work adds to the emerging category of venom-derived peptides with dual therapeutic applications, complementing ongoing AI-driven antimicrobial peptide discovery efforts disclosed at AACR 2026 and ESCMID 2026.
A new Nature Biomedical Engineering paper introduces HMD-AMP, a protein language model-based approach that outperforms prior methods at identifying evolutionarily distant antimicrobial peptides. Applied to host and gut microbiome genomes of nine mammals, HMD-AMP revealed over 37 million predicted AMPs. Of 91 experimentally validated high-confidence sequences, 74 showed strong antibacterial activity and 48 were evolutionarily remote from known AMPs, including four with broad-spectrum activity at low toxicity.
The European Society of Clinical Microbiology & Infectious Diseases (ESCMID) Global 2026 opened today at Messe München, running April 17-21 with ~18,000 international participants. Antimicrobial resistance dominates the agenda, with presentations featuring novel antimicrobial peptides, peptide-antibody hybrids, and AI-driven AMP discovery platforms. ESCMID is the largest international clinical microbiology and infectious diseases conference worldwide.
A Nature Communications paper introduces CAMPER (Constraint-driven AMP Engineering with Ranking), a mechanistic AI framework that integrates machine learning with biophysical ranking to design membrane-targeting peptides against MRSA persisters and biofilms. The framework identified WP-CAMPER1, a 12-mer peptide that kills S. aureus MW2 at an MIC of 4 µg/mL; a 2% topical formulation reduced S. aureus burden by 2.5 log10 in a murine skin infection model.
A Nature Communications paper published April 15 reveals shared structural mechanisms between SbmA — an E. coli membrane transporter that imports antimicrobial peptides — and ABC transporters. Using cryo-electron microscopy, EPR spectroscopy, and molecular dynamics simulations, researchers demonstrated SbmA undergoes ABC-transporter-like conformational changes, informing strategies to design antibiotic-resistant-bacteria-penetrating peptide drugs.
A comprehensive review in Discover Oncology highlights antimicrobial peptides' emerging dual role as anticancer and antiviral therapeutics. AMPs selectively target cancer cell membranes through electrostatic interactions while also demonstrating antiviral activity, with their immunomodulatory properties and reduced resistance development offering advantages over conventional chemotherapy.
A study in Nature Microbiology used a generative protein language model (ProteoGPT) to discover novel antimicrobial peptides effective against multidrug-resistant bacteria. The AI-designed peptides showed comparable or superior efficacy to clinical antibiotics in mouse infection models, with reduced resistance development and no organ damage.
UC launched a clinical trial using Peptilogics' peptide-based antimicrobial agent to treat prosthetic joint infections by targeting bacterial biofilms that have resisted traditional therapies.